Valuation: Dermata Therapeutics, Inc.

Market Cap 4.55M 4.06M 3.79M 3.44M 6.48M 440M 6.53M 45.53M 17.79M 224M 17.06M 16.69M 719M P/E 2026 *
-0.52x
P/E 2027 * -0.79x
Enterprise Value 4.55M 4.06M 3.79M 3.44M 6.48M 440M 6.53M 45.53M 17.79M 224M 17.06M 16.69M 719M EV / Sales 2026 *
45.5x
EV / Sales 2027 * 6.06x
Free-Float
72.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.44%
1 week+2.73%
Current month+2.73%
1 month-9.60%
3 months-19.86%
6 months-16.30%
Current year-51.29%
1 week 1.06
Extreme 1.06
1.16
1 month 1.06
Extreme 1.06
1.31
Current year 0.95
Extreme 0.9509
4.66
1 year 0.95
Extreme 0.9509
5.18
3 years 0.95
Extreme 0.9509
149.97
5 years 0.95
Extreme 0.9509
16,679.99
10 years 0.95
Extreme 0.9509
16,679.99
Manager TitleAgeSince
Chief Executive Officer 67 2014-12-07
Director of Finance/CFO 48 2021-08-31
Investor Relations Contact - -
Director TitleAgeSince
Chairman 67 2021-03-31
Director/Board Member 77 2014-12-07
Director/Board Member 78 2016-09-19
Date Insider Type Main position Quantity % Market Cap. Importance
8/16/26 Free

Chief Financial Officer

306,120 10.7966%
2/17/26 Buy

General Counsel

1,000 0.0353%
1/2/26 Free

Director

2,500 0.0940%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.73%-74.78%-99.21% 4.55M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.57% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.07%-2.60%+329.29%+684.92% 42.84B
-0.58%-3.81%+28.76%+29.61% 42.79B
+0.33%-0.48%+6.61%+110.77% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
+0.54%-1.75%-8.94%-11.65% 24.05B
Average +0.22%-0.23%+40.49%+100.17% 39.43B
Weighted average by Cap. +0.68%-0.54%+56.16%+128.63%

Financials

2026 *2027 *
Net sales 100K 89.35K 83.36K 75.72K 143K 9.67M 144K 1M 391K 4.92M 375K 367K 15.82M 750K 670K 625K 568K 1.07M 72.55M 1.08M 7.51M 2.94M 36.9M 2.82M 2.75M 119M
Net income -11.08M -9.9M -9.24M -8.39M -15.8M -1.07B -15.92M -111M -43.37M -545M -41.61M -40.71M -1.75B -13.78M -12.32M -11.49M -10.44M -19.66M -1.33B -19.8M -138M -53.94M -678M -51.74M -50.62M -2.18B
Net Debt - -
Projected Income Statement - Annual - Dermata Therapeutics, Inc.
Logo Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Employees
9
Date Price Change Volume
26-10-07 US$1.130 0.00% 6,630
26-10-06 US$1.130 +1.80% 29,585
26-10-05 US$1.110 +0.45% 14,158
26-10-02 US$1.105 -0.45% 18,309
26-10-01 US$1.110 +0.91% 21,049
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.130USD
Average target price
4.000USD
Spread / Average Target
+253.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermata Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. DRMA Stock